Brief: Herantis Pharma: Successful HER-096 Initial Results With Nanoform Technology

Herantis Pharma Oyj

24/03/2022 07:05

March 24 (Reuters) - Herantis Pharma Oyj  HRTIS.HE :
    * HERANTIS PHARMAANNOUNCES SUCCESSFUL HER-096 INITIAL
RESULTS WITH
NANOFORM TECHNOLOGY
    * RESULTS OF PROOF-OF-CONCEPT STUDY DEMONSTRATING SUCCESSFUL
NANOFORMING OF HER-096 INTO NANOPARTICLES
    * SUBCUTANEOUS ADMINISTRATION WILL BE USED IN HERANTIS'
HER-096
FIRST-IN-HUMAN CLINICAL STUDY THAT IS EXPECTED TO COMMENCE IN
2023

Source text for Eikon:  ID:nWkr5rKTzJ 
Further company coverage:  HRTIS.HE 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))